<qa>  What is the primary analysis of the patient?As secondary analyses, the investigators will: 1 assess the risk of all-cause mortality associated with DOAC use compared to warfarin use in the 3 months after cohort entry; 2 assess the risk of major bleeding associated with DOAC use compared to warfarin use, according to chronic kidney disease status; 3 determine descriptively the proportion of patients who experienced a major bleeding event by major bleed type; and 4 stratify the primary analysis by age less than 66, 66-75, 76-85 and greater than 85, sex, and use of an anti-platelet medication in the 90 day period prior to cohort entry. 